
Dec 19 (Reuters) - Pharma Mar SA PHMR.MC:
SAID ON THURSDAY, IT GOT FDA'S (U.S. FOOD AND DRUG ADMINISTRATION) APPROVAL FOR INVESTIGATIONAL NEW DRUG APPLICATION
APPROVAL MEANS START OF PHASE 1/2 MULTICENTER CLINICAL TRIAL IN U.S.
TRIAL TO EVALUATE COMBINATION OF PM54 WITH IMMUNOTHERAPY FOR TREATMENT OF ADVANCED-STAGE SOLID TUMORS
PHASE 1 TO FOCUS ON SAFETY EVALUATION
PHASE 2 TO ASSES SAFETY AND EFFICACY
Further company coverage: PHMR.MC